Ligand-receptor-mediated drug delivery: An emerging paradigm in cellular drug targeting

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 18, Issue 1, 2001, Pages 1-76

  Vyas, S P ^a   Singh, Amarjit ^b,c   Sihorkar, V ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

^c Panacea Biotec   (India)

Author keywords

Drug delivery; Ligand; Ligand mediated targeting; Receptor; Receptor mediated endocytosis

Indexed keywords

ANTIBODY; CLATHRIN; DRUG CARRIER; EPIRUBICIN; EPITOPE; FC RECEPTOR; INTERLEUKIN RECEPTOR; LECTIN RECEPTOR; LIGAND; LIPOPROTEIN RECEPTOR; OLIGOSACCHARIDE; POLYPEPTIDE; PRODRUG; SCAVENGER RECEPTOR; TRANSFERRIN RECEPTOR; VIRUS PROTEIN;

DRUG DELIVERY SYSTEM; DRUG TARGETING; ENDOCYTOSIS; GENE TARGETING; LIGAND BINDING; RECEPTOR UPREGULATION; REVIEW;

EID: 0035053829     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v18.i1.10     Document Type: Review

References (328)

1. Liposomes in drug delivery: Clinical, diagnostic and ophthalmic potential
2. Targeting of drugs: Implications in medicine
3. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome encapsulated amphotericin-B
4. Enhanced intracytoplasmic killing of Brucella abortus in bovine 4 mononuclear cells by liposomes containing gentamycin
5. Immunological adjuvants: A role of liposomes
6. Passive vectoring of a colloidal carrier system for sodium stibogluconate preparation, characterisation and performance evaluation
7. Pressurized pack-based liposomes for pulmonary targeting of isospronaline-development and characterization
8. Preparation and characterization of niosomes containing rifampicin for lung targeting
9. Multiple emulsion-based systems for prolonged delivery of rifampicin: In vitro and in vivo characterization
10. Supramolecular biovectors: Development and characterization
11. Organ-directed toxicology of antitumor agents
12. The influence of emulsifying agents on the phagocytes by macrophages
13. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a blockcopolymer polaxamine 908
14. Inverse targeting of drugs to reticuloendothelial system-rich organs by lipid microemulsion emulsified with polaxamer 338
15. Monovalent antibody-chromophore conjugates as selective phototoxins
16. Targetable photoactivable drugs: II. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymer-anti-Thy 1.2 antibody-chlorin e6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro
17. Antibody-targeted photolysis: Selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorine e6 conjugates
18. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH sensitive poly (ethylene glycol) derivative
19. Preparation and characterisation of dextran magnetite-incorporated thermosensitive liposomes: An on-line flow system for quantifying magnetic responsiveness
20. pH sensitivity and plasma stability of liposomes containing N-stearoylcysteamine
21. In vivo characterization of indomethacin magnetic polymethyl methacrylate nanoparticles
22. Magnetically responsive diclofenac-sodium loaded erythrocytes
23. Cellular interaction in the generation of cytotoxic T-lymphocyte response: Role of Ia-positive splenic adherent cells in presentation of H-2 antigen
24. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein
25. Carbohydrate-specific receptors of the liver
26. The biochemical and physiological characteristics of receptors
27. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier
28. Insulin fragments as a carrier for peptide delivery across the blood brain barrier
29. Angiotensin II receptors and angiotensin II receptors antagonists
30. Targeting of drugs to various blood cell using (neo)-glycoproteins, antibodies and other protein carriers
31. Ligand-targeted liposomes
32. Coupling of ligands with liposome membranes
33. Antibody-directed liposomes as drug-delivery vehicles
34. Irreversible coupling of immunoglobulin fragments to preformed vesicles: An improved method for liposome targeting
35. Use of an anti-horseradish peroxidase antibody gold complex in the ABC technique
36. Generic liposome reagent for immunoassays
37. Avidin- and streptividin-containing probes
38. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor
39. A two-step targeting approach for delivery of doxorubicin loaded liposomes to tumor cells in vivo
40. Receptor mediated endocytosis
41. Endocytosis
42. Endocytosis
43. Receptor cell biology: Receptor-mediated endocytosis
44. Nonspecific adsorptive pinocytosis
45. Endocytosis and lysosome: Recent progress in intracellular traffic
46. The role of clathrin, adaptors and dynamin in endocytosis
47. Fate of receptor and ligand during endocytosis of asialoglycoproteins by isolated hepatocytes
48. Receptor mediated endocytosis
49. Clathrin-coated pits and coated vesicles: Functional and structural studies
50. Human IgG Fc receptor
51. Signal-dependent membrane protein trafficking in the endocytic pathway
52. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. Prolonged persistence in cytoplasmic vesicles after partial hepatectomy
53. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis
54. The emergence of clathrin-independent pinocytic pathways
55. Potocytosis: Sequestration and transport of small molecules by caveolae
56. Potocytosis of small molecules and ions by caveolae
57. Endocytosis of GPI-linked membrane folate receptor-alpha
58. The coated pit and macropinocytic pathways serve distinct endosome population
59. Cytoplasmic coat proteins involved in endosome function
60. Endocytic pathway in polarized Caco-2 cells: Identification of an endosomal compartment accessible from both apical and basolateral surface
61. Membrane protein trafficking through the common apical endosome compartment of polarized Caco-2 cells
62. Apical and basolateral endosome of MDCK cells are incorporated and contain a polarized sorting mechanism
63. Selective regulation of apical endocytosis in polarized Mandin-Darby canine kidney cells by mastoparan and cAMP
64. Novel applications of liposomes
65. Regulation of protein traffic in polarized epithelial cells
66. Receptor-mediated transcellular transport of immunoglobulins
67. Transepithelial transport of immunoglobulins
68. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor
69. Identification and characterization of a novel protein (p137) which transcytose bidirectionally in Caco-2 cells
70. Specific targeting of high density lipoprotein to liver hepatocytes by incorporation of a tris-galactoside-terminated cholesterol derivative
71. Transcytosis-associated protein (TAP)/p115 is a general fusion factor required for binding of vesicles to acceptor membranes
72. The establishment of polarity and enhanced transcytosis of transferrin receptors in enterocyte-like Caco-2 cells
73. Effects of brefeldin A on endocytosis, transcytosis and transport to the Golgi complex in polarized MDCK cells
74. Regulation of insulin receptor internalization in vascular endothelial cells by insulin and phorbol ester
75. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
76. Insulin-sensitive tyrosine kinase: Relationship with in vivo insulin action in humans
77. β-adrenergic receptor kinase: Identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor
78. Recycling receptors: The round trip itinerary of malignant membrane proteins
79. The transcytosis approach
80. Acidification of endocytic compartments and the intracellular pathways of ligand and receptors
81. Insulin degradation: Mechanisms, products and significance
82. Processing of insulin by bovine endothelial cells in culture: Internalization without degradation
83. Native and modified lipoproteins as drug delivery systems
84. Liposome targeting in animal models: Problems and opportunities
85. The receptosomes: An intermediate organelle of receptor-mediated endocytosis in cultured fibroblasts
86. Characterization of the early endosome and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro
87. Late endosome derive from early endosome by maturation
88. Monensin and chloroquine inhibit transfer to lysosomes of endocytosed macromolecules in cultured mouse peritoneal macrophages
89. The entry of enveloped viruses into cells by endocytosis
90. Pseudomonas exotoxin-anti TAC: Cell-specific immunotoxin active against cells expressing the human T-cell growth factor receptor
91. Monensin inhibits intracellular dissociation of asialoglycoproteins from their receptor
92. Subcellular characterization of the endocytosis of small oligomers of mouse immunoglobulin G in murine macrophages
93. Plasmid DNA adsorbed to pH-sensitive liposome efficiently transforms the target cells
94. Advances in receptor mediated gene transfer into cells in vitro and in vivo
95. Diacytosis of human asialotransferrin type 3 by isolated rat hepatocytes
96. Microtubules and microtubule-associated proteins
97. Microtubule-dependent motor proteins: New targets for drug delivery
98. Molecular motors and their role in membrane traffic
99. Two activators of microtubule-based vesicle transport
100. Targeting of motor proteins
101. Molecular motors, membrane movements and physiology: Emerging roles for myosins
102. Vertebrate unconventional myosins
103. Unconventional myosins
104. Receptor-mediated delivery of foreign genes to hepatocytes
105. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hepatocholesterolemia in LDL-receptor deficient rabbits
106. Depolymerization of hepatocellular microtubules after partial hepatectomy
107. Microtubular disruption prolongs the expression of human bilirubin-UDPG transferase-1 gene transfected into Gunn rat livers
108. Actin- and microtubule-dependent organelle motors: Interrelationships between the two motility systems
109. Lectins as cell recognition molecules
110. Carbohydrate-mediated liposomal targeting and drug delivery
111. Glyco-conjugates as carriers for specific delivery of therapeutic drugs and genes
112. Carbohydrate-structure-dependent Willis recognition of desialylated serum glycoproteins in the liver and leukocytes. Two complementary systems
113. Drug targeting for antiviral agents: Options and limitations
114. Endogenous lectins and drug targeting
115. Membrane lectins on human monocytes: Maturation dependent modulation of 6-phosphomannose and mannose receptors
116. Membrane lectins of human lymphocytes
117. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins
118. The asialoglycoprotein receptor: A model for endocytic transport receptors
119. The hepatic asialoglycoprotein receptor
120. Receptor-mediated delivery of drugs to hepatocytes
121. Specific targeting of HDL to liver hepatocytes by incorporation of a Tris-galactoside terminated cholesterol derivative
122. Lactosylceramide induced stimulation of liposome uptake by Kupffer cells in vitro
123. The effect of water soluble trisgalactoside terminated cholesterol derivative on the in vivo fate of small unilamellar vesicles in rats
124. Alteration of liposome disposition in vivo by bilayer situated carbohydrates
125. Drug-polymer conjugates: Potential for improved chemotherapy
126. Targeting of liposomes towards different cell types of rat liver through the involvement of liposomal surface glycolipids
127. Model for specific rescue of normal hepatocytes during methotrexate treatment of hepatic malignancy
128. Acetaminophen hepatotoxicity and targeted rescue: A model for specific chemotherapy of hepatocellular carcinoma
129. Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to aialofetuin
130. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system
131. Neoglycoprotein: The preparation and application of synthetic glycoproteins
132. Receptor-mediated endocytosis
133. Receptor-mediated pinocytosis of mannose/N-acetylglucosamine terminated glycoproteins and lysosomal enzymes by macrophages
134. Mannose-specific oligosaccharide recognition by mononuclear phagocytes
135. Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate-recognition domains
136. Clearing up glycoprotein hormones
137. Mannose-6-phosphate receptors and lysosomal targeting
138. Lysosomal enzyme binding to mouse P388 D1 macrophage membranes lacking the 215 kDa mannose-6-phosphate receptor: Evidence for the existence of a second mannose-6-phosphate receptor
139. Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconyl residues as macrophage activators
140. Selective uptake of liposomes by different cell-types of liver through the involvement of liposome surface glycosides
141. Role of surface glycolipids - Natural or synthetic origin on the biodistribution of liposomes
142. Liposome targeting to mouse brain: Mannose as a recognition marker
143. Antitumor properties and reduced toxicity of LPS targeted to macrophages via normal or mannosylated liposomes
144. Plasma membrane receptors of the mononuclear phagocytic systems
145. Cell surface lectins of human granulocytes: Their expression is modulated by mononuclear cells and granulocytes/macrophage colony stimulating factor
146. Soluble human lymphocyte sugar binding proteins with immunosuppressive activity
147. Cell surface receptors for sulfated polysaccharides: A potential marker for macrophage subsets
148. A β-glucan inhibitable receptor on human monocyte: Its identity with the phagocytic receptor for particulate activators of the alternative complement pathway
149. Production and isolation of rabbit and-idiotypic antibodies directed against the human monocyte receptor for yeast β-glucans
150. A lymphocyte homing receptor is a lectin, a member of the emerging LEC-CAM family
151. Lymphocyte homing receptors and vascular addressins
152. Carbohydrate ligands of the LEC cell adhesion molecules
153. The selectins and their ligands
154. Regulation and lectin activity of the human neutrophil peripheral lymph node homing receptor
155. Sulfated glycolipids are ligands for a lymphocyte homing receptor, L-selectin (LECAM-1), binding epitope in sulfated sugar chain
156. Molecular characterization of the human macrophage mannose receptor: Demonstration of multiple carbohydrate recognition-like domains and phagocytosis of yeasts in Cos-1 cells
157. Transition from monocytes to tissue macrophages results in altered expression of Fc receptor activity
158. Bone marrow macrophage precursors: I. Some functional characteristics of early cells of the mouse macrophage series
159. Structural aspect and heterogeneity of immunoglobulin Fc receptor
160. Human neutrophil Fc receptor distribution and structure
161. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cell, and effective means of inhibiting virus replications in vitro
162. Effect of negatively charged lipids on phagocytosis of liposomes opsonized by complements
163. A newly developed immunoliposomes - An egg phosphatidylcholine liposome coated with pullulan bearing both a cholesterol moiety and an IgM fragment
164. Biological activity of oligonucleotide-poly-L-lysine conjugates: Mechanism of cell uptake
165. Plug and seal: Prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes
166. Long circulatory (sterically stabilized) liposomes for targeted drug delivery
167. Sterically stabilized vesicles
168. Doxorubicin in sterically stabilized liposomes
169. Targeted delivery of doxorubicin via sterically stabilized immuno-liposomes: Pharmacokinetics and biodistribution in tumor bearing mice
170. Antibody-complement interaction with lipid model membranes
171. Kinetics of antibody-mediated binding of haptenated phospholipid vesicles to a macrophage-related cell line
172. Specific targeting of phototoxic haptenated liposomes to a hapten specific B cell lymphoma
173. Deposition of C3b and iC3b onto particulate activators of the human complement system
174. A human leukocyte differentiation family with distinct alpha-subunits and a common beta-subunit: The lymphocyte function-associated antigen (LFA-1), the C3b complement receptor (OKM1.MAC-1) and the p150.95 molecule
175. Complement receptor structure and function
176. Tumor- promoting phorbol esters stimulate C3b and C3bi receptor-modified phagocytosis in cultured human monocytes
177. Complement receptors and phagocytosis
178. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten
179. Activation of human complement by liposome: A model for membrane activation of the alternative pathway
180. Liposome-complement interactions in rat serum: Implications for liposome survival studies
181. Liposome clearance from blood: Different animal species have different mechanisms
182. Complement activation in rats by liposome and liposome-encapsulated hemoglobin: Evidence for antilipid antibodies and alternative pathway activation
183. Liposome-induced activation of the classical complement pathway does not require immunoglobulin
184. Antibody-dependent, complement mediated liver uptake of liposome containing GM1
185. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes
186. Serum opsonins and liposomes: Their interaction and opsonophagocytosis
187. Only high affinity receptors for interleukin 2 mediate internalization of ligand
188. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines
189. Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor
190. Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in murine Meth A sarcoma model
191. Interleukin-2 in liposomes: Increased intravenous potency and less pulmonary toxicity in the rat
192. Enhancement of antitumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2
193. Molecular design of polymer-conjugated cytokines and its application for drug delivery system
194. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes
195. The development of IL-2 conjugated liposomes for therapeutic purposes
196. Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases
197. Selective effectiveness of galactose-containing liposome IL-2 on liver lymphocytes
198. Stabilization and enhancement of IL-2 in vitro bioactivity by new carriers: Supramolecular biovectors
199. Interferon-gamma enhances expression of cellular receptors for tumor necrosis factor
200. Potentiation of tumor necrosis factor-mediated cytotoxicity on human myeloid cell lines: Effects of interferons versus dimethylsulphoxide
201. Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres
202. Dermal and transdermal delivery of protein pharmaceuticals: Lipid-based delivery systems for interferon alpha
203. Preparation of asialo-fetuin-labeled liposomes with encapsulated human interferon-gamma and their uptake by isolated rat hepatocytes
204. Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody
205. Liver targeting of interferon through pullulan conjugation
206. (Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting
207. Tumor vascular endothelium: Barrier or target in tumor directed drug delivery and immunotherapy
208. Structure-function studies on selectins carbohydrate ligands. Modification to fucose, sialic acid and sulfate as a sialic acid replacement
209. Carbohydrate ligands of the LEC cell adhesion molecules
210. Intercellular immune adhesion molecules in human liver transplants: Overview on expression patterns of leucocyte receptors and ligand molecules
211. A receptor-mediated pathway for cholesterol homeostasis
212. The biochemistry of lipoproteins
213. Regulation of scavenger receptor, class B, type I, a high-density lipoprotein receptor, in liver and steroidogenic tissue of the rat
214. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport
215. Cells involved in removing liposomes from the blood circulation: Why they are so special?
216. Fate of injected liposomes: Observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo
217. The role of surface charge and hydrophilic groups on liposome clearance in vivo
218. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo
219. Apolipoprotein B of plasma lipoproteins incorporated in liposomes: Immunological properties and organ distribution when administered to rabbits
220. Conjugation of apolipoprotein B with liposomes and targeting to cells in culture
221. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages
222. A novel mechanism for achieving transgene persistence in vivo after somatic gene transfer into hepatocytes
223. Self-assessing supramolecular biovectors: A new dimension in novel drug delivery systems
224. Scavenging for receptors
225. Type I macrophage receptor contains a-helical and collagen-like coiled ccoils
226. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface
227. Pharmacokinetics of succinylated proteins and dextran sulfate in mice: Implications for hepatic targeting of protein drugs br direct succinylation via scavenger receptors
228. Macromolecular carrier systems for targeted drug delivery: Pharmacokinetic considerations on biodistribution
229. Evidence that the scavenger receptor is not involved in the uptake of negatively charged liposomes by cells
230. The class B scavenger receptor SR-B1 and CD36 are receptors for anionic phospholipids
231. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
232. A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: Partial purification and role in recognition of oxidatively damaged cells
233. Glyoaldehyde-modified low density lipoprotein leads macrophages to foam cells via the macrophage scavenger receptor
234. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes
235. Transferrin as a targeting ligand for liposomes and anticancer drugs
236. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor
237. Brain drug delivery of small molecules using immunoliposomes
238. Cell surface receptor directed targeting of toxin to human malaria parasite, Plasmodium falciparum
239. Production and characterization of fusion proteins containing transferrin and nerve growth factor
240. Efficiency of targeted gene delivery of ligand-poly-L-lysine hybrids with different crosslinks
241. Gene delivery into human cancer cells via transferrin receptor
242. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications in anti-HIV antisense drug delivery to the brain
243. Genetically engineered brain drug delivery vectors: Cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptividin fusion gene and protein
244. Folate-mediated targeting of therapeutic and imaging agents to cancers
245. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin
246. Intercellular immune adhesion molecules in human liver transplants: Overview on expression patterns of leucocyte receptors and ligand molecules
247. Adhesion molecules: A new target for immunoliposome-mediated drug delivery
248. Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity
249. Adhesion molecules, part I
250. Adhesion molecules, part II
251. Cadherin/catenin complex: A target for anti-invasive therapy
252. Integrin dependent signal transduction
253. The vitronectin receptor (alpha v beta 30 as an example for the role of integrins in T lymphocyte stimulation
254. Regulation of integrin function
255. RGD and other recognition sequences for integrins
256. Involvement of integrins in cell survival
257. Review: The integrins alpha v beta 3: Angiogenesis and apoptosis
258. Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo
259. High-affinity self-reactive antibodies by design and selection: Targeting the integrin ligand binding site
260. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryo neovascularization
261. Development of a new angiogenesis-specific liposome particle for use in diagnostic imaging and drug delivery
262. Arginyl-glycyl-aspartic acid (RGD): A cell adhesion motif
263. Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor cell arrest in lungs followed by extravazation
264. Interaction of RGD liposomes with platelets
265. Peptide attachment to extremities of liposomal grafted PEG chains: Preparation of the long-circulating form of laminin pentapeptide, YIGSR
266. Selectins
267. Endothelial-leucocyte adhesion molecules in human disease
268. Traffic signals for lymphocyte recirculation and leucocyte emigration: The multistep paradigm
269. Selectins-carbohydrate interactions and the initiation of the inflammatory response
270. Role of selectins, a new family of adhesion molecules, in ischemia-reperfusion injury
271. Adhesion molecules and inflammatory injury
272. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis (X) oligosaccharide
273. Oligonucleotides as research, diagnostic, and therapeutic agents
274. Folate-binding protein is a marker for ovarian cancer
275. Targeting folate receptor with folate linked to the extremities poly (ethylene glycol)-grafted liposomes: In vivo studies
276. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis
277. Folate-mediated tumor-cell targeting of liposome-entrapped doxorubicin in vitro
278. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments
279. Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia
280. Liposomal targeting of leukemia HL 60 cells induced by transferrin-receptor endocytosis
281. Transferrin conjugated PEG-liposomes as intracellular targeting carrier for tumor therapy
282. Synthesis of transferrin-Mitomycin C as a receptor-mediated drug targeting system
283. Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of the bladder cancer
284. Soluble polymers for lectin-mediated targeting
285. Native and modified lipoproteins as drug delivery systems
286. Characterization of epidermal growth factor receptor gene expression in malignant and normal cell lines
287. Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinoma using anti-EGF recepto antibody: Immunogen approach
288. Targeting of liposomes to cells bearing nerve growth factor receptors mediated by biotinylated nerve growth factor
289. Endoglin is an endothelial cell proliferation marker that is selectively expressed in tumor vasculature
290. Early intervention in cancer using monoclonal antibodies and other biological ligands: Micropharmacology and the "binding site carrier"
291. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells
292. Clinical evidence of effective tumor targeting based on a single chain Fv antibody selected from a combinatorial library
293. Identification of monoclonal antibody, TV1-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin-2
294. Radio-immunotherapy with 90Y-labelled monoclonal antibodies in a nude mouse ovarian cancer model
295. Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy
296. A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug Epirubicin-Glucuronide for specific treatment of cancer
297. Advanced drug delivery reviews: Enzyme prodrug therapy
298. Hybrid antibodies can target sites for attack by T-cells
299. Bispecific antibodies
300. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain
301. Reduction of EGP-2 positive pulmonary metastases by bispecific antibody redirected T-cells in an immunocompetent rat model
302. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
303. Tumor infarction: Immunoconjugates that coagulate the vasculature of solid tumors
304. Specific interaction of CD4-bearing liposomes with HIV-infected cells
305. Targeting of liposomes to HIV-1 infected cells by peptides derived from the CD4 receptor
306. Liposomes with incorporated MHC class II/peptide complex as antigen presenting vesicles for specific T cell activation
307. Inhibition of HIV-replication by pokeweed anti-viral protein targeted to CD-4+ cells by monoclonal antibodies
308. Immunoconjugates that neutralize HIV virions kill T-cells infected with diverse strains of HIV-1
309. Selective killing of HIV-infected cells by anti-gp120 immunotoxins
310. Treatment of HIV tissue culture infection with monoclonal antibody ricin A chain conjugates
311. Human immunodeficiency virus infected T-cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain
312. Murine monoclonal antibodies directed against the transmembrane protein gp41 of human deficiency virus type-1 enhance its infectivity
313. Soluble CD-4 enhances the efficacy of immunotoxins directed against gp41 of human deficiency virus
314. HIV-infected cells are killed by rCD4 ricin A chain
315. Immunotoxins: New therapeutic reagents for autoimmunity, cancer, and AIDS
316. Hepatic membrane receptor for glycoproteins
317. Sequence and expression of a membrane associated C-type lectin that exhibits CD4 independent binding of human immunodeficiency virus envelope glycoprotein gp120
318. Mannosyl/N-acetyl-b-D-glucosaminyl binding properties of the envelope glycoprotein op HIV type-II
319. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice
320. Signal transduction and nuclear targeting: Regulation of transcription factor activity by subcellular localization